<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04305535</url>
  </required_header>
  <id_info>
    <org_study_id>EC032-19_FJD</org_study_id>
    <nct_id>NCT04305535</nct_id>
  </id_info>
  <brief_title>Impact of an Oligomeric Diet in Intestinal Absorption and Inflammatory Markers in Patients With Crohn Disease</brief_title>
  <official_title>Clinical Trial to Evaluate the Effect of an Oligomeric Oral Nutritional Supplement on the Response in Intestinal Absorption and Inflammation, in Patients With CROHN Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Adventia Pharma, S.L.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Biopolis S.L.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, multicenter, translational, triple-blind, clinical trial in patients
      with Crohn's disease, who will be prescribed an oral nutritional supplement to control
      symptoms in the acute phase and to recover in the remission phase.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multicentric, parallel, randomized, double blind and controlled clinical-nutritional study of
      6 months of intervention and 3 study groups of treatment: Experimental group (peptidic diet
      with a mix of probiotics); Experimental group with placebo (peptidic diet with a placebo);
      and Control group (control with a polymeric nutritional oral supplement with a placebo) to
      evaluate the effect on the nutritional status, inflammatory markers and the intestinal
      absorption
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 13, 2020</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">February 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Malabsorption</measure>
    <time_frame>6 months</time_frame>
    <description>Body Weight Change (kg)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in the consistency of the stools according to Bristol scale.</measure>
    <time_frame>6 months</time_frame>
    <description>Bristol scale: type 1= separate hard lumps, type 2= sausage shaped but lumpy, type 3= like a sausage but with cracks on ots surface, type 4= like a sausage or sanake, smooth and soft, type 5= soft blobs with clear cut-edges, type 6= fluffy pieces with ragged edges, a mushy stool, type 7 = watery, no solid pieces.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fat malabsorption</measure>
    <time_frame>6 months</time_frame>
    <description>Presence of fat in the stool</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">162</enrollment>
  <condition>Crohn Disease</condition>
  <condition>Absorption; Disorder, Protein</condition>
  <condition>Absorption; Disorder</condition>
  <condition>Absorption; Disorder, Fat</condition>
  <condition>Absorption; Disorder, Carbohydrate</condition>
  <condition>Malnutrition</condition>
  <arm_group>
    <arm_group_label>Peptidic+Probiotic</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Nutritional intervention and dietary recommendations. Consumption of 2 tetra paks/day of a specific oral nutritional supplement and mix of probiotics during 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Peptidic+Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Nutritional intervention and dietary recommendations. Consumption of 2 tetra paks/day of a specific oral nutritional supplement and placebo during 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Polymeric+Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Nutritional intervention and dietary recommendations. Consumption of 2 tetra paks/day of a specific oral nutritional supplement and placebo during 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Peptidic+Probiotic</intervention_name>
    <description>Oligomeric oral nutritional supplement (Bi1 peptidic) and a mix of probiotics
Bifidobacterium animalis subsp. lactis BPL1,
Lactobacillus rhamnosus BPL15,
Lactobacillus rhamnosus CNCM i-4036
Bifidobacterium longum ES1</description>
    <arm_group_label>Peptidic+Probiotic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Peptidic+Placebo</intervention_name>
    <description>Oligomeric oral nutritional supplement (Bi1 peptidic) and a placebo</description>
    <arm_group_label>Peptidic+Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Polymeric+Placebo</intervention_name>
    <description>Polymeric oral nutritional supplement and a placebo</description>
    <arm_group_label>Polymeric+Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Unintentional weight loss of 5% in 6 months or a BMI less than 20kg/m2 or does not get
             the energy requirements with normal food.

          -  Willing to comply with the prescribed diet follow-up for CD.

        Exclusion Criteria:

          -  Having received antibiotics in the previous 3 months

          -  Having undergone intestinal resection surgery≥70-75%

          -  Refuse to participate in the study

          -  Comorbidity that allows to suspect survival &lt;1 year
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Miguel Aganzo-Yeves, RD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario Fundación Jiménez Díaz</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Clotilde Vázquez-Martínez, MD</last_name>
    <role>Study Director</role>
    <affiliation>Hospital Universitario Fundación Jiménez Díaz</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Miguel A Aganzo-Yeves, RD</last_name>
    <phone>+34661774925</phone>
    <email>miguel.aganzo@fjd.es</email>
  </overall_contact>
  <location>
    <facility>
      <name>Miguel Aganzo Yeves</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miguel A Aganzo-Yeves, RD</last_name>
      <phone>+34661774925</phone>
      <email>miguel.aganzo@fjd.es</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 5, 2020</study_first_submitted>
  <study_first_submitted_qc>March 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 12, 2020</study_first_posted>
  <last_update_submitted>March 11, 2020</last_update_submitted>
  <last_update_submitted_qc>March 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Oligomeric diet</keyword>
  <keyword>Peptidic diet</keyword>
  <keyword>Probiotics</keyword>
  <keyword>Oral Nutritional Supplements</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
    <mesh_term>Malnutrition</mesh_term>
    <mesh_term>Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

